Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback